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Abstract 
Context: Mitochondria are essential for cellular energy homeostasis, yet their role in 
subcutaneous adipose tissue (SAT) during different types of weight-loss interventions 
remains unknown.
Objective: To investigate how SAT mitochondria change following diet-induced and 
bariatric surgery–induced weight-loss interventions in 4 independent weight-loss studies.
Methods: The DiOGenes study is a European multicenter dietary intervention with an 
8-week low caloric diet (LCD; 800 kcal/d; n  =  261) and 6-month weight-maintenance 
(n  =  121) period. The Kuopio Obesity Surgery study (KOBS) is a Roux-en-Y gastric 
bypass (RYGB) surgery study (n = 172) with a 1-year follow-up. We associated weight-
loss percentage with global and 2210 mitochondria-related RNA transcripts in linear 
regression analysis adjusted for age and sex. We repeated these analyses in 2 studies. 
The Finnish CRYO study has a 6-week LCD (800-1000 kcal/d; n = 19) and a 10.5-month 
follow-up. The Swedish DEOSH study is a RYGB surgery study with a 2-year (n = 49) and 
5-year (n = 37) follow-up.
Results: Diet-induced weight loss led to a significant transcriptional downregulation 
of oxidative phosphorylation (DiOGenes; ingenuity pathway analysis [IPA] z-scores: 
−8.7 following LCD, −4.4 following weight maintenance; CRYO: IPA z-score: −5.6, all 
P < 0.001), while upregulation followed surgery-induced weight loss (KOBS: IPA z-score: 
1.8, P < 0.001; in DEOSH: IPA z-scores: 4.0 following 2 years, 0.0 following 5 years). We 
confirmed an upregulated oxidative phosphorylation at the proteomics level following 
surgery (IPA z-score: 3.2, P < 0.001).
Conclusions: Differentially regulated SAT mitochondria-related gene expressions 
suggest qualitative alterations between weight-loss interventions, providing insights 
into the potential molecular mechanistic targets for weight-loss success.
Key Words: adipose tissue, mitochondria, weight loss, diet-induced, bariatric surgery, transcriptomics
Obesity, one of the largest public health threats globally (1), 
associates with various debilitating diseases, including type 
2 diabetes (T2DM), cardiovascular disorders, and some 
cancers (2, 3).
Weight loss effectively reduces health risks among 
people who are overweight or with obesity. A  moderate 
body weight reduction of 5% to 10% induced through 
dieting significantly reduces disease risk and improves the 
metabolic profile (4). However, long-term weight mainten-
ance resulting from lifestyle interventions remains rather 
poor (5). Bariatric surgery, while more invasive, leads to 
greater weight losses and more often to T2DM remission 
compared with diet-induced weight loss (6, 7). Reductions 
in body weight are predominantly due to the loss of adi-
pose tissue, although the underlying processes responsible 
for adipose tissue function during weight loss and mainten-
ance following different types of interventions are poorly 
understood.
Mitochondrial function in subcutaneous adipose tissue 
(SAT) may be an important contributor responding to 
energy balance changes following weight loss. SAT mito-
chondrial oxidative metabolism is diminished in obesity 
(8-10)—a phenomenon that likely associates with both the 
persistence of the obesity phenotype and the development 
of obesity-related metabolic diseases (11). Previously, we, 
and others, reported a downregulation of mitochondria-
related pathways in diet-induced weight loss and mainten-
ance (12, 13), with findings that remain inconsistent (14, 
15). In contrast, an increased SAT mitochondrial capacity 
was observed following surgically induced weight loss (16-
18), indicating that bariatric surgery may cause a metabol-
ically more advantageous change to the SAT mitochondrial 
function than dieting. This implies that SAT mitochondrial 
activity could impact the mechanism explaining more suc-
cessful weight maintenance following different intervention 
types, while the true long-term effects are unclear.
Furthermore, weight-loss interventions are generally diffi-
cult to reconcile and one contributing factor stems from dif-
ferences in the degree of weight loss achieved following an 
intervention. Studies focusing on the comprehensive charac-
terization of SAT mitochondria, using standardized analysis 
pipelines for different types of long-term weight-loss inter-
ventions, are lacking. Here, we aimed to retrospectively in-
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SAT following 2 diet-induced and 2 bariatric surgery–induced 
weight-loss interventions. We performed a standardized set of 
bioinformatics analyses, considering the percentage weight 
loss across all study cohorts. In addition, we analyzed the SAT 
proteome following surgery-induced weight loss.
Research Design and Methods
Study Designs
The Diet, Obesity and Genes (DiOGenes) study is a 
multicenter, randomized, dietary intervention study 
(ClinicalTrials.gov ID number NCT00390637) (19). 
Briefly, 938 healthy adults with overweight or obesity 
(body mass index [BMI] 27-45 kg/m2) without concomi-
tant medications followed a low-calorie diet (LCD; 800 
kcal/day) for 2 months. Participants who lost ≥8% of their 
body weight were subsequently assigned to 1 of 5 diets (a 
2 × 2 factorial combination diet of low/high protein and a 
low/high glycemic index or a control diet) in the 6-month 
weight-maintenance phase. Altogether, 548 participants 
completed both phases. Here, we examined data from 314 
participants, for whom abdominal SAT RNA sequencing 
data from at least 2 time points were available. Weight and 
metabolic health were assessed at baseline, 2 months, and 
8 months.
The Kuopio OBesity Surgery (KOBS) is a prospective 
observational study investigating the metabolic conse-
quences of obesity surgery (20). The study criteria were (1) 
a BMI ≥ 40 kg/m2, or BMI ≥ 35 kg/m2 with an obesity-
associated comorbidity; (2) a failure of traditional obesity 
treatments; and (3) no other surgical contraindications. 
Here, we report analyses from 172 participants (34% with 
T2DM) who underwent Roux-en-Y gastric bypass (RYGB) 
surgery and for whom abdominal SAT RNA sequencing 
data were available at baseline and at 12 months follow-up. 
Additionally, we studied SAT proteomics in a subset of 29 
individuals without T2DM, respectively. Weight and meta-
bolic health were assessed at baseline and 12 months.
CRYO is a case-control dietary intervention study 
(ClinicalTrials.gov ID NCT01312090) (12, 21, 22), util-
ized to replicate our findings on diet-induced weight loss. 
Briefly, 19 adults with obesity and no concomitant medi-
cations lost weight through a 6-week modified LCD (800-
1000 kcal/day), followed by a weight-maintenance phase 
with daily reductions of 500 to 1000 kcal from their pre-
LCD diet until 12 months. SAT microarrays, weight, and 
metabolic health were assessed at baseline, 5 months, and 
12 months.
To replicate our findings on surgery-induced weight 
loss, we utilized the Effects of Different Surgical Methods 
to Treat Obesity (DEOSH) study (ClinicalTrials.gov ID 
NCT01785134). This study (23) consisted of 82 females 
with morbid obesity (BMI ≥ 40 kg/m2) or BMI ≥ 35 kg/m2 
with obesity-related comorbidities who underwent RYGB 
surgery. Here, we analyzed data for 49 individuals for 
whom abdominal SAT microarray data were available, to-
gether with assessment of weight and metabolic health at 
baseline and 2 and 5 years.
The ethical approvals were obtained from the ethics 
committees of each center/country for the multicenter 
DiOGenes cohort, from the Northern Savo Hospital 
District, Kuopio, Finland for KOBS, from the hospital dis-
tricts Helsinki and Uusimaa, as well as Southwest Finland, 
Finland for CRYO, and from the Karolinska Institutet in 
Stockholm, Sweden for the DEOSH study. All studies ad-
hered to the Helsinki Declaration regarding participants’ 
informed consent.
Adipose Tissue Biopsy, RNA Preparation, and 
Transcriptomics Analyses
In all studies, SAT biopsy specimens were snap-frozen in li-
quid nitrogen and stored at −80 °C until further analysis. In 
DiOGenes, after an overnight fast, abdominal SAT needle 
biopsies were collected 6 to 8 cm laterally from the umbil-
icus under local anesthesia. Total RNA was extracted and 
analyzed as described elsewhere (24, 25). For each sample, 
gene expression was then examined using 100-nucleotide-
long paired-end RNA sequencing with an Illumina HiSeq 
2000 of libraries prepared using the Illumina TruSeq kit. 
We used GenomicAlignments to retrieve the number of 
reads mapping onto 53  343 genes (GRCh37 assembly). 
Only reads with both ends mapping onto a single gene were 
considered (24, 25).
In KOBS, abdominal SAT baseline samples involved open 
biopsies taken during surgery, while 12-month postsurgical 
samples were collected as open biopsies under local an-
esthesia. Total RNA was extracted and purified using the 
miRNeasy Mini Kit. RNA sequencing libraries were con-
structed with the TruSeq Stranded mRNA Library Prep Kit 
and underwent 69-nucleotide-long paired-end sequencing 
on the Illumina HiSeq 4000 machine at a depth of 40 to 
50 M reads per sample. The Rsubread R package was used 
to count all reads mapping onto a final list of 15 014 genes 
(GRCh38 assembly). Only reads with both ends mapping 
onto a single gene were considered.
In CRYO, periumbilical SAT biopsies were obtained 
surgically under local anesthesia after an overnight fast. 
Total RNA was extracted and the global transcript profiles 
of SAT were analyzed using Affymetrix HG-U133 Plus 2 
microarrays (12).
In DEOSH, abdominal SAT biopsy specimens were 
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follow-up. Total RNA was extracted and global transcript 
profiles of SAT were analyzed using ClariomTM D arrays 
(Affymetrix, Santa Clara, CA, USA) (26).
SAT Protein Isolation, LC-ESI-MS/MS Preparation, 
and Proteome Analysis in KOBS
Proteins were extracted from the SAT specimens by hom-
ogenizing the tissue with a TissueLyser LT instrument 
(QIAGEN) in a lysis buffer containing broad-range pro-
tease and phosphatase inhibitors. We collected the pro-
tein fraction under the lipid layer and determined the 
concentrations. Because the SAT specimens contained 
blood contaminants, we depleted the high-abundant 
serum proteins and again determined concentrations. 
Next, we performed in-solution digestion with trypsin, 
sodium deoxycholate removal, desalting, and peptide 
elution, after which equal amounts of total protein were 
prepared. Liquid chromatography electrospray ionization 
tandem mass spectrometric (LC-ESI-MS/MS) analysis 
was conducted on a nano-high-performance liquid chro-
matography (HPLC) system (Easy-nLC1200) coupled to 
the Q Exactive HF mass spectrometer (Thermo Fisher 
Scientific, Bremen, Germany) equipped with a nano-
electrospray ionization source using the data-dependent 
operation mode.
Statistical Analyses
Anthropometric and clinical variables
Changes in anthropometric and clinical parameters before 
and after interventions were analyzed using a mixed-model 
ANOVA (DiOGenes, CRYO and DEOSH) applying the re-
stricted maximum likelihood (REML) method (27). The 
participant ID was used as a random factor, selecting the 
unstructured covariance structure. The Bonferroni post hoc 
correction was used for comparisons between timepoints. 
In KOBS, changes in anthropometric and clinical vari-
ables were analyzed using paired samples t-tests, in which 
skewed variables were loge-transformed before analysis. We 
considered p < 0.05 statistically significant.
Differential RNA expression analyses
The DiOGenes dietary intervention and the KOBS 
bariatric surgery intervention were used as the discovery 
material, while we used the CRYO and DEOSH cohorts 
as the diet- and surgery-induced replication datasets, 
respectively.
First, to determine the effects of weight loss on the global 
SAT transcriptomics profiles of the DiOGenes and KOBS 
cohorts, we performed differential expression analysis 
using the linear model (package limma and limma-voom in 
R-Bioconductor (28)). We identified the altered transcripts 
that associated with weight-loss percentage (%) within 
each participant (from before and after intervention). In 
both cohorts, we adjusted the regression model for sex and 
age, and in DiOGenes, additionally for study center and 
sequencing center. In KOBS, we further adjusted the model 
for technical covariates. We corrected P values for multiple 
testing (Benjamini and Hochberg method (29)) and con-
sidered a false-discovery rate (FDR) P < 0.05 statistically 
significant.
Second, we performed a targeted differential expres-
sion analysis on transcripts affecting mitochondria, based 
on 2210 genes selected from the MitoMiner 4.0 database 
(30). We applied the same statistical models as above for 
the mitochondria-targeted analyses for DiOGenes and 
KOBS, and then repeated them in the CRYO and DEOSH 
datasets. We identified the significantly altered gene expres-
sions (CRYO: FDR P < 0.05; DEOSH nominal P < 0.05) 
that associated with weight-loss percentage, adjusted for 
sex (CRYO) and age (CRYO and DEOSH).
Next, we identified individuals with 15% to 20% 
weight loss in DiOGenes and KOBS and repeated the tar-
geted mitochondrial differential expression analysis using 
the same statistical models as above.
SAT proteomics data normalization and differential 
expression analysis
We analyzed the effects of weight loss on the SAT prote-
omics in a subset (n = 29) of the KOBS cohort. Data pre-
processing included the removal of blood proteins (31) 
and resulted in 1204 identified proteins, for which we per-
formed differential expression analysis using a linear model 
(package limma in R-Bioconductor). Significantly changed 
protein expressions (nominal P < 0.1) that associated with 
weight-loss percentage within each participant were identi-
fied and adjusted for sex and age.
Biological pathway analyses
We further investigated significantly changed genes and 
proteins identified from the differential analyses using 
the ingenuity pathway analysis tool (IPA) (August 2019, 
Ingenuity Systems, Redwood City, CA, USA).
Associations between mitochondria-related gene 
expression and clinical variables in DiOGenes and KOBS
We calculated standardized beta coefficients between the 
delta (postintervention minus baseline) oxidative phos-
phorylation (OXPHOS) pathway score and the delta 
clinical outcome measures using linear regression ana-
lysis (model 1). The OXPHOS score was calculated by 
averaging, for each person, the z-scores of the 102 genes 
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and age (including study center and sequencing center 
for DiOGenes) as covariates. Skewed clinical variables 
were loge-transformed. In model 3, a dimension re-
duction was performed on the gene expressions in the 
OXPHOS pathway using principal component analysis 
(PCA). We performed a linear regression adjusted for sex 
and age (including study center and sequencing center 
for DiOGenes) using normalized gene expression values, 
retaining only enough principal components (PCs) (3 in 
DiOGenes and 2 in KOBS) to account for 80% of the 
total variances captured. We considered P < 0.05 statis-
tically significant.
All data were analyzed using SPSS for Mac (version 
24.0; SPSS Inc., Chicago, IL, USA) or R statistical program-
ming language (version 3.3.3).
Results
Participant Characteristics and Weight Loss
The DiOGenes dietary intervention and the KOBS 
bariatric surgery intervention were used as the discovery 
material, while we used the CRYO and DEOSH cohorts, 
respectively, as diet- and surgery-induced replication 
datasets. Table 1 summarizes the anthropometric and 
clinical characteristics of the discovery studies, while 
Supplemental Table 1 (32) provides the characteristics of 
the replication studies. Across all cohorts, participants 
lost significant amounts of weight (P < 0.001). The clin-
ical measures for lipid metabolism and insulin sensitivity 
primarily reflected changes in weight and were ameli-
orated in all studies (Table 1 and Supplemental Table 1 
(32)).
In DiOGenes, average weight loss reached 11.2% ± 2.8% 
following LCD and 11.9% ± 7.1% following the weight-
maintenance period (Table 1). In CRYO, participants lost 
on average 11.5% ± 5.3% weight after the 5-month and 
9.0%  ±  7.2% after the 12-month period (Supplemental 
Table 1 (32)). In KOBS, average weight loss reached 
22.4%  ±  7.7% at 12  months after surgery (Table 1), 
while in DEOSH, average weight loss was 31.6% ± 9.3% 
at 2  years and 27.5%  ±  10.4% at 5  years after surgery 
(Supplemental Table 1 (32)).
SAT Mitochondrial Gene Pathways Changed in 
Opposing Directions in Global Transcriptomics 
Analyses
We first explored changes in the global transcriptomics pat-
terns in SAT using regression analysis against the weight-
loss percentage in DiOGenes and KOBS. In DiOGenes, 
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significant associations (FDR P <  0.05) between the 
weight-loss percentage and gene transcripts; among these, 
1378 (12%) were mitochondria-related (Supplemental 
Table 2 (32)). Following the weight-maintenance phase 
(8  months), we identified 9622 associations, of which 
11% were mitochondria-related (Supplemental Table 2 
(32)). In KOBS, we identified 8756 associations between 
the weight-loss percentage and gene transcripts at base-
line and 12 months after surgery, of which 1197 (14%) 
were mitochondria-related (Supplemental Table 3 (32)).
To gain insight into the biological pathways, we used 
IPA on the top (FDR P-sorted) 2000 differentially ex-
pressed transcripts associated with weight-loss percentage. 
Interestingly, both weight-loss interventions showed signifi-
cant differences in the mitochondrial gene–related path-
ways (Fig. 1). The OXPHOS pathway was among the top 10 
(using the Fisher’s exact P) significantly enriched pathways 
in both cohorts, resulting in opposing activation predic-
tion scores (DiOGenes z-score −5.4 vs KOBS z-score 6.7). 
Tricarboxylic acid cycle (TCA) cycle II, sirtuin signaling, 
and the NRF2-mediated oxidative stress response were also 
significantly changed after both diet- and surgery-induced 
weight loss (data not shown).
Analyses of Differentially Expressed 
Mitochondria-Related Genes
We subsequently focused on 2210 mitochondria-targeting 
genes by extracting them from the MitoMiner database 
(30). Using FDR P < 0.05 as the cutoff, we found that the 
weight-loss percentage following the LCD phase in the 
DiOGenes cohort significantly associated with a change 
in 1437 transcripts, 65% of which were downregulated 
(Supplemental Table 4 (32)). Between baseline and 
8 months, we found 1173 associations, 61% of which were 
downregulated. By contrast, in KOBS, we identified 1194 
significant associations, mostly involving upregulated 
transcripts (70%) following weight loss between baseline 
and 12 months (Supplemental Table 4 (32)). Additionally, 
in KOBS, we stratified the cohort for T2DM status. The 
direction of mitochondria-related transcripts remained 
similar, although the statistical power was diminished in 
the smaller subgroups (Supplemental Table 5 (32)). These 
results indicate that the majority of transcripts targeting 
mitochondria were affected by the weight-loss percentage 
in DiOGenes and KOBS, although in opposing directions.
Next, we used the CRYO (diet-induced) and DEOSH 
(surgery-induced) cohorts to reproduce the mitochondrial 
results in SAT, finding similar patterns as those observed in 
DiOGenes and KOBS. Although these replication studies 
were smaller in size, both studies had longer follow-up 
periods than DiOGenes and KOBS. In CRYO, we found 
that most (75%) of the 581 associations between the 
weight-loss percentage and transcripts were downregulated 
(Supplemental Table 6 (32)). In contrast, in DEOSH, most 
of the significant (nominal P <  0.05) transcripts were 
upregulated following weight loss both between baseline 
and 24 months (96% of 483 transcripts) and between base-
line and 5  years (81% of 120 transcripts) (Supplemental 
Table 7 (32)).
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Figure 1. Gene enrichment for biological pathways using significantly differentially expressed global genes associated with the weight-loss per-
centage following the diet-induced weight-loss DiOGenes study (n = 121) (A) and the surgery-induced weight-loss KOBS study (n = 171) (B). The top 
10 significant pathways from the ingenuity pathway analysis (IPA) tool (P < 0.001) for both cohorts are presented. For several pathways, IPA provided 
z-scores for the pathway directionality by calculating the observed number of “activated” genes (z-score > 0), “inhibited” genes (z-score < 0), or 
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OXPHOS Pathway Downregulated Following 
Diet-Induced, but Upregulated Following 
Surgery-Induced Weight Loss
At the pathway level, we found a strong downregulation of 
the OXPHOS pathway in the dietary-induced DiOGenes 
cohort (z-scores: −8.7 at 2 months vs baseline and −4.4 at 
8 months vs baseline), but an upregulation in the surgery-
induced KOBS cohort (z-score: 1.8). These findings persisted 
in the CRYO cohort (z-score: −5.6) and the DEOSH cohort 
(z-score: 4.0 for 24 months vs baseline), but not 60 months 
vs baseline. The top 10 (sorted based on the Fisher’s exact 
P) IPA pathways, for which a pathway emerged in at least 
2 comparisons, appear in Fig. 2a.
Since the OXPHOS pathway was significantly differ-
ently regulated by the 2 weight-loss intervention types, we 
next examined the individual transcripts for that pathway 
across the 4 respective cohorts. The overall pattern clearly 
reveals a downregulation of the transcripts in the dietary-
induced interventions (DiOGenes and CRYO) and an 
upregulation in the surgery-induced interventions (KOBS 
and DEOSH), suggesting opposing effects on the mito-
chondrial respiratory machinery (Fig. 3).
Genes encoding the 5 OXPHOS complexes originate 
both from the nucleus and mitochondria. To this end, 
it is noteworthy that the majority of the top 10 most 
downregulated transcripts in DiOGenes and the majority 
of the top 10 most upregulated transcripts in KOBS in the 
OXPHOS pathway were encoded by mitochondrial DNA 
(mtDNA) (based on fold changes) (Supplemental Table 4 
(32)). In both studies, MT-ND1, MT-ND2, producing com-
plex I NADH dehydrogenase subunits, and MT-CO1, the 
primary subunit of the cytochrome c oxidase (IV) complex, 
emerged as the most differentially expressed mitochondria-
encoded transcripts.
Other Enriched Mitochondrial-Related Pathways 
in Diet- and Surgery-Induced Weight Loss
The TCA cycle II, fatty acid β-oxidation I, and branched-
chain amino acid (BCAA) degradation pathways were also 
significantly changed following weight loss (Fig. 2a). We 
observed a downregulation of mitochondria-related path-
ways specifically in all diet-induced weight-loss cohorts, 
where the TCA cycle pathway represented the second most 
predicted downregulated pathway (z-scores:  <  2). The 
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Figure 2. Gene enrichment for biological pathways using significantly differentially expressed mitochondria-related genes associated with the 
weight-loss percentage following diet- and surgery-induced weight loss across all studies (in total, 6 postintervention vs baseline comparisons) (A) 
and in groups matched for 15% to 20% weight loss from the diet-induced weight-loss DiOGenes study (n = 24) and surgery-induced weight-loss 
KOBS study (n = 34) (B). In (A), we selected the top 10 significant pathways from the ingenuity pathway analysis (IPA) tool (P < 0.001) from each 
comparison; the pathway results are shown when present in at least 2 of 6 of the top 10 selections. In (B), the results are presented for the top 10 
significant pathways from the IPA tool (P < 0.001) from both studies. For several pathways, IPA provided z-scores for the pathway directionality by 
calculating the observed number of “activated” genes (z-score > 0), “inhibited” genes (z-score < 0), or no directionality (z-score = 0). Z-scores > 2 
or < −2 were considered significant. Results are ranked according to biological function. In (A), gradients indicated by blue bars (from dark to light 
blue) indicate diet-induced weight-loss comparisons: DiOGenes 2 months vs baseline (n = 261); DiOGenes 8 months vs baseline (n = 121); and CRYO 
12 months vs baseline (n = 19). Gradients indicated by red bars (from dark to light red) indicate the surgery-induced weight-loss studies: KOBS, 
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Figure 3. Heat map showing the differential expression of the individual genes in the oxidative phosphorylation (OXPHOS) pathway associated 
with weight-loss percentage following diet- and surgery-induced weight loss. Log2-fold changes indicated for the 5 primary complexes of the elec-
tron transport chain genes. The color in the heat maps reflect the differential expressions associated with the weight-loss percentage before and 
after weight loss, where red indicates up- and blue indicates downregulation. Asterisks indicate statistically significant differential expressions: 
***P < 0.001; **P < 0.01; *P < 0.05. Gray squares indicate unmeasured transcripts. The 3 left-most columns show the diet-induced weight-loss com-
parisons: DiOGenes, 2 months vs baseline (n = 261); DiOGenes, 8 months vs baseline (n = 121); and CRYO, 12 months vs baseline (n = 19). The 3 
right-most columns show the surgery-induced weight-loss studies: KOBS, 12 months vs baseline (n = 171); DEOSH, 24 months vs baseline (n = 49); 







/article/106/5/1312/6131733 by guest on 11 August 2021
1320  The Journal of Clinical Endocrinology & Metabolism, 2021, Vol. 106, No. 5
mitochondria-related pathways in the surgery-induced co-
horts varied more in their responses than the diet-induced 
cohorts (Fig. 2a). Nevertheless, the activation prediction 
score for these mitochondria-related pathways consist-
ently indicated a downregulation for diet-induced and an 
upregulation for surgery-induced weight loss.
Consistently Opposing Mitochondria-Related 
Patterns Among Groups Matched for Weight-Loss 
Percentage
Although the results above were derived from analyses 
examining weight-loss percentage, we further addressed 
the possibility that our findings resulted from the larger 
amount of weight loss in bariatric surgery interventions. To 
this end, we identified individuals with similar weight-loss 
percentage (15%-20%) at the end of follow-up among the 
DiOGenes and KOBS cohorts.
We compared the mitochondria-related gene expression 
differences associated with weight-loss percentage at 8 months 
(DiOGenes: n = 24, 58% female, mean age: 43 ± 7 years, 
mean weight loss: 17.2 ± 1.5%) and at 12 months (KOBS: 
n = 34, 65% female, mean age: 49 ± 7 years, mean weight 
loss: 17.4  ±  1.4%) vs baseline, respectively. Based on the 
FDR P < 0.05 cutoff, we identified 657 associations between 
weight-loss percentage and changes in transcript expression, 
most (74%) of which were downregulated in DiOGenes. In 
KOBS, we found 270 associations, most (79%) of which were 
upregulated (Supplemental Table 8 (32)). At the pathway 
level, we again found a downregulation of OXPHOS tran-
scripts following diet-induced weight loss (z-score: −5.6) 
and an upregulation following surgery-induced weight loss 
(z-score: 6.4) (Fig. 2b). Moreover, the TCA cycle II pathway 
also significantly changed in opposing directions (z-score: 
>|2|); the fatty acid β-oxidation I  and BCAA degradation 
pathways changed in opposing directions, although not stat-
istically significantly. This consistency in results suggests that 
our findings did not result from weight-loss differences re-
lated to the interventions.
SAT Mitochondria-Related Proteins Upregulate 
Following Surgical Intervention
To determine if the transcriptomics results following 
surgery-induced weight loss remained consistent at other 
levels, we examined the SAT proteome in 29 individuals 
from the KOBS cohort. We analyzed weight-loss percentage 
with the protein expression postoperatively, finding that 284 
of 1204 identified SAT proteins expressed significantly dif-
ferently (nominal P < 0.1, Supplemental Table 9 (32)), 95% 
of which were upregulated. Moreover, 101 (30%) of the 
significantly changed proteins were mitochondria-related, 
all upregulated. Likewise, the OXPHOS pathway was in 
the top 10 significantly enriched pathways with a predicted 
upregulation (z-score: 3.2) (Fig. 4a); individual OXPHOS 
proteins also revealed a consistent upregulation (Fig. 4b). 
Other top 10 pathways were related to ethanol and me-
tabolite degradation. Additionally, 57 of these differentially 
expressed proteins associated with genes were also signifi-
cantly differentially regulated at the transcriptional level in 
the KOBS cohort (Supplemental Table 9 (32)).
Association of Mitochondria-Related Gene 
Expression With Clinical Characteristics
Finally, following the transcriptome analyses, we studied 
the relationship between SAT mitochondria-related gene 
expression and improvements in clinical characteristics fol-
lowing weight loss. Following the 8-month DiOGenes inter-
vention, the change in the combined score for 102 genes in 
the OXPHOS pathway (OXPHOS score) negatively associ-
ated with LDL cholesterol and positively with HDL choles-
terol as well as improvements in insulin sensitivity measures 
(Supplemental Table 10, model 1 (32)). Similar associations 
were observed for HDL in KOBS. Following further ad-
justments for age and sex (Supplemental Table 10, model 2 
(32)), only the association between the OXPHOS score and 
HDL remained significant. These results imply that a rela-
tive increase in the OXPHOS pathway following weight 
loss may associate with improved metabolic outcomes.
We also analyzed the associations between the OXPHOS 
pathway and clinical parameters using a dimension reduction 
by PCA. PC1 (composed of 57 genes, Supplemental Table 11 
(32)) and PC3 (24 genes) significantly associated with changes 
in HDL, total cholesterol, and fasting insulin in the DiOGenes 
cohort (Supplemental Table 10, model 3 (32)). In the KOBS 
cohort, PC2 (22 genes) associated with HDL and fasting glu-
cose (Supplemental Table 10, model 3 (32)). Interestingly, all 
mitochondria-encoded genes clustered together in the same 
PC (PC3 in DiOGenes and PC2 in KOBS, Supplemental Table 
11 (32)). Overall, these associations suggest a relationship be-
tween changes in OXPHOS transcripts and clinical improve-
ments following weight loss in both interventions.
Discussion
In this study, we investigated how the SAT transcrip-
tional capacity for mitochondria changed following 
diet- and surgery-induced interventions in 4 independent, 
pan-European weight-loss studies using a standardized 
set of bioinformatics analyses. Our findings show that 
mitochondria-related gene expression is regulated in 
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induced weight loss with a long-term follow-up. Specifically, 
diet-induced weight loss downregulated, while surgery-
induced weight loss upregulated mitochondrial oxidative 
metabolism (based on global transcriptomics and pathway 
analyses). We observed the strongest effects in mtDNA-
encoded mRNA transcripts. Additionally, we confirmed 
upregulated mitochondrial oxidative metabolism at the 
protein level following surgery-induced weight loss.
The finding that diet-induced weight loss leads to an 
apparent transcriptional downregulation of SAT oxidative 
metabolism is intriguing and slightly counterintuitive, since 
adipose tissue is known to be a low oxygen-consuming 
tissue (33). Previously, we showed that mitochondrial 
density and OXPHOS complex III protein levels decreased, 
particularly in individuals who continuously lost weight 
following the 12-month dieting; yet, we observed no effects 
on other OXPHOS proteins or mtDNA transcripts (12). 
The downregulation of oxidative pathways may contribute 
to or be a consequence of other cellular disruptions, such as 
those related to lipid metabolism, energy partitioning and 
oxidative stress response following weight loss (13, 25). 
On a more functional level, one study reported indirect 
Figure 4. SAT mitochondria-related proteins were upregulated following surgical intervention. Protein enrichment for biological pathways using dif-
ferentially expressed proteins (nominal P < 0.1) associated with the weight-loss percentage following surgery-induced weight loss in KOBS (n = 29) 
(A), the top 10 significant findings from the ingenuity pathway analysis (IPA) tool (P < 0.001) are shown. For several pathways, IPA provided z-scores 
for pathway directionality by calculating the observed number of “activated” genes (z-score > 0), “inhibited” genes (z-score < 0), or no directionality 
prediction (z-score = 0). Z-scores > 2 or < −2 were considered statistically significant. Results ranked according to statistical significance. In (B), a heat 
map showing the differential expression of the individual proteins in the oxidative phosphorylation (OXPHOS) pathway associated with weight-loss 
percentage following surgery-induced weight loss. Log2-fold changes indicated for the 5 primary complexes of the electron transport chain proteins. 
Only measured proteins are shown. The color in the heat maps reflect the differential expressions associated with the weight-loss percentage before 
and after weight loss, where red indicates up- and blue indicates downregulation. Asterisks indicate statistically significant differential expressions: 
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evidence for SAT mitochondria changes following diet-
induced weight loss through a reduction in the SAT oxygen 
pressure (34). However, SAT mitochondrial functional 
alterations remain to be studied to elucidate biological 
mechanisms since no studies have directly measured mito-
chondrial respiration from fresh SAT biopsies following 
diet-induced weight loss.
After bariatric surgery, we observed a consistent and 
significant upregulation of the OXPHOS pathway in SAT. 
In the short-term weight-loss response, within 1 week to 
3 months, an increased expression of the genes involved 
in mitochondrial biogenesis was observed following 
gastric bypass surgery (but not gastric banding) (16). 
Furthermore, the SAT expression of OXPHOS genes ap-
peared to increase at 3 months following gastric bypass 
(35). In the longer term, at the 1-year postoperative time 
point, relatively small studies demonstrated that gastric 
bypass surgery increased the SAT gene expression in the 
mitochondrial metabolic and OXPHOS pathways (18, 
36). Our results here confirm and extend these findings, 
since our weight-loss studies included more individuals 
(KOBS) and longer follow-up periods (DEOSH). Notably, 
our proteomics results further confirm the increased 
OXPHOS findings at the posttranscriptional level. The 
beneficial effects of bariatric surgery on SAT mitochon-
drial oxidative metabolism may be mediated by multiple 
signals. Bile acids (37), gut hormones (38), fibroblast 
growth factors 19 and 21 (39), and microbiome-related 
products including short-chain fatty acids (40) represent 
the most promising candidates to explain such changes 
since their levels are altered to a greater degree after 
bariatric surgery compared with diet-induced weight 
loss. Furthermore, surgery-induced weight loss also leads 
to a greater reduction in adipocyte size when compared 
with diet-induced weight loss. This may positively influ-
ence the mitochondrial oxidative metabolism given that 
a relatively greater hyperplasia follows surgery (23).
Since the transcriptional capacity of mitochondria 
changed following weight loss, we hypothesized that this 
would affect SAT function and thus whole-body physi-
ology. Therefore, we studied the relationship between 
OXPHOS gene expression in SAT and improvements to 
clinical characteristics following weight loss. We found 
similar associations between the OXPHOS score and the 
mitochondria-encoded genes with insulin sensitivity–re-
lated measures in the DiOGenes and KOBS cohorts. 
Nevertheless, the small effect sizes in our results also in-
dicate that diet- and surgery-induced weight loss result 
in clinical improvements through mechanisms not dir-
ectly dependent on the transcriptional capacity of SAT 
mitochondria.
The primary strength of this study lies in our reliance 
on 4 independent weight-loss interventions: the large 
DiOGenes (diet-induced) and KOBS (surgery-induced) 
studies for our primary analyses, and the smaller CRYO 
and DEOSH studies to replicate the findings. Importantly, 
we used weight-loss percentage as the primary explanatory 
variable, adjusted for sex and age, thereby accounting for 
differences in the degree of weight loss achieved following 
intervention. We confirmed our findings in the matched 
15% to 20% weight-loss groups in DiOGenes and KOBS. 
Although, at the time of the biopsies, the energy balance of 
the study participants could have varied, it is likely that on 
average a stable weight had been achieved at the long-term 
timepoints. Additionally, while our results primarily stem 
from transcriptomics, we could validate our findings at the 
protein level in the surgery-induced KOBS study. Follow-up 
studies should examine the functional consequences of 
long-term weight loss on SAT mitochondrial activity and 
function, since posttranscriptional and/or translational 
regulatory mechanisms could also be affected.
In conclusion, this study shows that long-term diet-
induced weight loss transcriptionally downregulated 
mitochondrial pathways in SAT. We also identified an op-
posite pattern among long-term weight loss induced by 
bariatric surgery supported by protein-level data. These 
data open new and exciting avenues for utilizing molecular 
mechanisms in SAT affected by different types of weight-
loss interventions, possibly leading to improved tailored 
weight-loss interventions. While both weight-loss methods 
induce impressive benefits on metabolic health, dieting car-
ries a significantly higher likelihood for long-term weight 
regain. Whether this propensity relates to the selective 
downregulation of mitochondrial oxidative metabolism in 
SAT requires clarity. Future studies are warranted to obtain 
detailed insight into mitochondrial function in SAT as a po-
tential target for weight-loss success.
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